Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,otherCurrentLiab,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,changeToOperatingActivities,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,exchange,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,marketState,market,shortName,exchangeDataDelayedBy,esgPopulated,tradeable,priceHint,regularMarketChangePercent,regularMarketDayRange,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 29, 2021) 4","Short Ratio (Jun 29, 2021) 4","Short % of Float (Jun 29, 2021) 4","Short % of Shares Outstanding (Jun 29, 2021) 4","Shares Short (prior month May 27, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,IMMP,46815880.0,64872500,,,-9922056,,-9922073,1558274,-3112372,-5197104,-5197104,,-1707,,,,18,1106291,6303394,4218662,-4724952,,-9922073,-9922073,13765097.0,15782610.0,60690939.0,76473549.0,277719728.0,38774.0,-291577359.0,1028837.0,109962.0,74548570.0,54880156.0,5214544.0,74548570.0,331436.0,62267054.0,5308783.0,9446391.0,4780542.0,,0.0,-6064.0,-60735.0,19315541.0,20116561.0,14279055.0,-511916.0,-4518507.0,526458.0,-3600.0,-740286.0,4877109.0,-2464.0,,,57052510.0,en-US,US,EQUITY,True,Delayed Quote,NGM,USD,4.07,1630526402,-0.1699996,4.1285,4.1765,3.95,616523,4.24,0.0,0.0,10,8,finmb_6701589,NasdaqGM,Immutep Limited,AUD,401837,390271,2.8500001,2.3360655,1.22 - 7.95,-3.8799996,-0.48805028,1.22,7.95,1482883200,PRE,us_market,Immutep Limited,0,False,False,4,-4.0094247,3.95 - 4.1765,-0.45,-0.27,0.94,3.5565715,0.5134287,0.14436057,3.6036956,0.46630454,0.1293962,264031088,-15.074074,4.3297873,15,America/New_York,EDT,-14400000,1.45,,,7.95,1.22,3.5566,3.6037,401.84k,390.27k,64.87M,,61.82M,0.00%,7.20%,531.41k,0.98,,0.82%,485.75k,,,,,,0.00%,"Dec 27, 2016",,1:10,"Nov 06, 2019","Jun 29, 2020","Dec 30, 2020",0.00%,-300.79%,-20.00%,-61.68%,6.35M,0.14,-76.90%,-6.66M,-17.07M,-27.36M,-0.4500,,54.88M,0.85,9.75M,16.07,11.94,0.94,-14.67M,-7.67M,Value,2000,Healthcare,"Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",Sydney,61 2 8315 7003,NSW,1609372800,Australia,http://www.immutep.com,86400,95 Pitt Street,61 2 8569 1880,Biotechnology,Level 12
t-1,IMMP,46815880.0,64872500,,,-9922056,,-9922073,1558274,-3112372,-5197104,-5197104,,-1707,,,,18,1106291,6303394,4218662,-4724952,,-9922073,-9922073,13765097.0,15782610.0,60690939.0,76473549.0,277719728.0,38774.0,-291577359.0,1028837.0,109962.0,74548570.0,54880156.0,5214544.0,74548570.0,331436.0,62267054.0,5308783.0,9446391.0,4780542.0,,0.0,-6064.0,-60735.0,19315541.0,20116561.0,14279055.0,-511916.0,-4518507.0,526458.0,-3600.0,-740286.0,4877109.0,-2464.0,,,57052510.0,en-US,US,EQUITY,True,Delayed Quote,NGM,USD,4.07,1630526402,-0.1699996,4.1285,4.1765,3.95,616523,4.24,0.0,0.0,10,8,finmb_6701589,NasdaqGM,Immutep Limited,AUD,401837,390271,2.8500001,2.3360655,1.22 - 7.95,-3.8799996,-0.48805028,1.22,7.95,1482883200,PRE,us_market,Immutep Limited,0,False,False,4,-4.0094247,3.95 - 4.1765,-0.45,-0.27,0.94,3.5565715,0.5134287,0.14436057,3.6036956,0.46630454,0.1293962,264031088,-15.074074,4.3297873,15,America/New_York,EDT,-14400000,1.45,,,7.95,1.22,3.5566,3.6037,401.84k,390.27k,64.87M,,61.82M,0.00%,7.20%,531.41k,0.98,,0.82%,485.75k,,,,,,0.00%,"Dec 27, 2016",,1:10,"Nov 06, 2019","Jun 29, 2020","Dec 30, 2020",0.00%,-300.79%,-20.00%,-61.68%,6.35M,0.14,-76.90%,-6.66M,-17.07M,-27.36M,-0.4500,,54.88M,0.85,9.75M,16.07,11.94,0.94,-14.67M,-7.67M,Value,2000,Healthcare,"Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",Sydney,61 2 8315 7003,NSW,1609372800,Australia,http://www.immutep.com,86400,95 Pitt Street,61 2 8569 1880,Biotechnology,Level 12
t-2,IMMP,18104538.0,64872500,,,-3758944,,-3758943,1623610,-2177877,-4358574,-4358574,,-2367,,,,0,2070587,6429160,4248463,599630,,-3758943,-3758943,15084845.0,13297907.0,33299345.0,46597252.0,233328553.0,34822.0,-275706061.0,1011578.0,109962.0,75676853.0,26322047.0,3364245.0,75676853.0,250571.0,31151874.0,3391728.0,8789113.0,1639661.0,1294706.0,-1063001.0,-2091.0,-8119.0,5649911.0,6000000.0,2902949.0,72003.0,-2816873.0,526709.0,-3600.0,-341970.0,368282.0,-2091.0,159865.0,950217.0,27787629.0,en-US,US,EQUITY,True,Delayed Quote,NGM,USD,4.07,1630526402,-0.1699996,4.1285,4.1765,3.95,616523,4.24,0.0,0.0,10,8,finmb_6701589,NasdaqGM,Immutep Limited,AUD,401837,390271,2.8500001,2.3360655,1.22 - 7.95,-3.8799996,-0.48805028,1.22,7.95,1482883200,PRE,us_market,Immutep Limited,0,False,False,4,-4.0094247,3.95 - 4.1765,-0.45,-0.27,0.94,3.5565715,0.5134287,0.14436057,3.6036956,0.46630454,0.1293962,264031088,-15.074074,4.3297873,15,America/New_York,EDT,-14400000,1.45,,,7.95,1.22,3.5566,3.6037,401.84k,390.27k,64.87M,,61.82M,0.00%,7.20%,531.41k,0.98,,0.82%,485.75k,,,,,,0.00%,"Dec 27, 2016",,1:10,"Nov 06, 2019","Jun 29, 2020","Dec 30, 2020",0.00%,-300.79%,-20.00%,-61.68%,6.35M,0.14,-76.90%,-6.66M,-17.07M,-27.36M,-0.4500,,54.88M,0.85,9.75M,16.07,11.94,0.94,-14.67M,-7.67M,Value,2000,Healthcare,"Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",Sydney,61 2 8315 7003,NSW,1609372800,Australia,http://www.immutep.com,86400,95 Pitt Street,61 2 8569 1880,Biotechnology,Level 12
t-3,IMMP,18104538.0,64872500,,,-3758944,,-3758943,1623610,-2177877,-4358574,-4358574,,-2367,,,,0,2070587,6429160,4248463,599630,,-3758943,-3758943,15084845.0,13297907.0,33299345.0,46597252.0,233328553.0,34822.0,-275706061.0,1011578.0,109962.0,75676853.0,26322047.0,3364245.0,75676853.0,250571.0,31151874.0,3391728.0,8789113.0,1639661.0,1294706.0,-1063001.0,-2091.0,-8119.0,5649911.0,6000000.0,2902949.0,72003.0,-2816873.0,526709.0,-3600.0,-341970.0,368282.0,-2091.0,159865.0,950217.0,27787629.0,en-US,US,EQUITY,True,Delayed Quote,NGM,USD,4.07,1630526402,-0.1699996,4.1285,4.1765,3.95,616523,4.24,0.0,0.0,10,8,finmb_6701589,NasdaqGM,Immutep Limited,AUD,401837,390271,2.8500001,2.3360655,1.22 - 7.95,-3.8799996,-0.48805028,1.22,7.95,1482883200,PRE,us_market,Immutep Limited,0,False,False,4,-4.0094247,3.95 - 4.1765,-0.45,-0.27,0.94,3.5565715,0.5134287,0.14436057,3.6036956,0.46630454,0.1293962,264031088,-15.074074,4.3297873,15,America/New_York,EDT,-14400000,1.45,,,7.95,1.22,3.5566,3.6037,401.84k,390.27k,64.87M,,61.82M,0.00%,7.20%,531.41k,0.98,,0.82%,485.75k,,,,,,0.00%,"Dec 27, 2016",,1:10,"Nov 06, 2019","Jun 29, 2020","Dec 30, 2020",0.00%,-300.79%,-20.00%,-61.68%,6.35M,0.14,-76.90%,-6.66M,-17.07M,-27.36M,-0.4500,,54.88M,0.85,9.75M,16.07,11.94,0.94,-14.67M,-7.67M,Value,2000,Healthcare,"Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",Sydney,61 2 8315 7003,NSW,1609372800,Australia,http://www.immutep.com,86400,95 Pitt Street,61 2 8569 1880,Biotechnology,Level 12
